Hyphens Pharma International Limited has successfully registered the botulinum toxin formulation Nabota® from Daewoong Pharmaceutical Co., Ltd. (Daewoong Pharmaceutical) in Singapore on 20 January 2023.
Botulinum toxin, commonly referred to as botox, is a neuromodulator for cosmetic use, such as facial wrinkle improvement. Nabota® is a premium high-purity botulinum toxin based on Daewoong Pharmaceutical’s patented Hi-PureTM technology that minimises impurities, and is characterised by its high safety, rapid effect, and uniform spreading power. Nabota® is approved by the U.S. Food and Drug Administration (“FDA”) and Hyphens Pharma will be handling distribution and sales in Singapore.
Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, said: “We are happy to partner
Daewoong Pharmaceutical to bring in Nabota®, as we see a growing demand for facial wrinkle improvement due to aging populations. With the addition of Nabota®, Hyphens Pharma continues to advance its position as ASEAN’s leading specialty pharmaceutical company.”
